What Standigm does

Standigm is a Seoul-headquartered AI drug discovery company founded in May 2015 that builds end-to-end platforms spanning novel target identification, compound design, and lead optimization for pharmaceutical and biotechnology clients. Its core architecture combines a biology platform (Standigm ASK, powered by a knowledge graph covering 70K+ nodes and 4M+ edges drawn from 36 public databases and 97K scientific publications) with a chemistry platform (Standigm BEST, integrating proprietary algorithms ChemMap, GPN, Monet, NoSH, and IDEA-STAR) and an integrated workflow layer (Standigm Magic). Standigm also maintains proprietary therapeutic programs across cancer (solid tumor), fibrosis (MASH, IPF), and aging (sarcopenia), and in 2023 opened an in-house synthesis lab to close the design-make-test loop.

The company monetizes through three streams: (1) AI SaaS and API platform subscriptions for STELLA, SPICA, QIP-ADMET, GT-AutoML, and ASK-LLM, distributed via a self-serve model with a 2-week free trial; (2) collaborative research services with pharmaceutical partners; and (3) long-tail licensing and out-licensing economics from its proprietary pipeline. Its customer base is anchored by Korean pharma majors (SK chemicals, Hanmi Pharmaceutical, HK inno.N, Samjin Pharmaceuticals) and a growing set of global research institutions (Milner Therapeutics Institute, Institut Pasteur Korea, KIST, Ewha Womans University, Ajou University Hospital). Go-to-market combines direct enterprise sales for pharma collaborations, product-led growth via SaaS, channel partnerships, and event-driven engagement (notably BIO Korea).

Standigm has raised $71.2M total across seed (2015, $280K), Series A (2016, ~$3M), Series B (2019, $11.6M) with SK Holdings strategic capital ($7.2M), and Series C (2021-2023, $46.4M) including Pavilion Capital ($10M, 2021) and SK Chemicals ($2.7M). It employs 51-100 people across Seoul, UK, and US offices, has been recognized by Gartner (Tech Innovator 2023), Forbes Korea (AI 50 2024), and Fast Company (World Changing Ideas 2022), and positions itself against larger tech entrants as a workflow-AI specialist.

Name

Standigm

Legal name

주식회사 스탠다임 (Standigm Inc.)

Website

https://standigm.com

Company type

Private

Founded year

2015

Operating status

Operating

Headcount range

51–100 employees

Short description

Standigm is a Seoul-based AI drug discovery company offering end-to-end workflow AI platforms for novel target identification, compound design, and lead optimization, serving global pharmaceutical companies, biotech firms, and research institutions through SaaS, APIs, and collaborative research.

Ownership category

akta.pro rank

Product category

AI Drug Discovery Software

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)

SIC

Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

AI/ML Platforms for Drug Discovery & Experiment Optimization (HLAGAJAO)

akta.pro secondary industry

Drug Discovery (Target ID/Validation & Hit Discovery) (HLAIALAA)

Keywords

• AI drug discovery
• Drug target identification
• Compound design
• Drug repurposing
• AI SaaS platform

Headquarters

HQ city

Seoul

HQ country

South Korea

HQ region

Asia

Offices1 record

Markets served

GTM type

B2B

Offering type

Software

Cost components

Personnel, Technology or R&D, Marketing or Sales, Operations, Infrastructure

Revenue model

1. AI SaaS & API Platform Services: Standigm generates revenue by offering AI platform services through cloud-based SaaS and API products including STELLA, QIP-ADMET, SPICA, GT-AutoML, and ASK-LLM. Customers pay for platform access to accelerate their drug discovery processes. The company offers free trials to drive adoption with conversion to paid subscriptions.
2. Proprietary Drug Pipeline Development: Standigm develops its own therapeutic asset pipeline through in-house and collaborative research projects targeting cancer (solid tumor), fibrosis (MASH, IPF), and aging (sarcopenia). Revenue is generated through out-licensing of candidates or commercial partnerships.
3. Collaborative Research Services: Standigm provides AI-driven drug discovery services to pharmaceutical partners under collaborative research agreements. Partners include SK chemicals, Hanmi Pharmaceutical, HK inno.N, and others. Services include novel target identification, hit-to-lead optimization, and workflow AI integration.

Pricing tiers

Go-to-market motion4 records

Distribution channels4 records

Marketing channels7 records

Core offering

Standigm builds and sells an end-to-end AI-driven drug discovery platform that combines a biology platform for novel drug target identification with a chemistry platform for designing and optimizing drug molecules. Its SaaS/API products (STELLA, SPICA, QIP-ADMET, GT-AutoML, ASK-LLM) and core platforms (Standigm ASK, BEST, Magic) are sold to pharmaceutical companies, biotech firms, and research institutions to accelerate drug discovery and reduce development timelines. The company also generates revenue through collaborative research services with pharmaceutical partners and proprietary drug pipeline development for out-licensing.

Product overview

Standigm is an AI drug discovery company offering an integrated platform architecture combining biology and chemistry platforms. The product portfolio includes Standigm ASK for novel target identification, Standigm BEST for compound design and hit-to-lead optimization, Standigm Magic for integrated workflow AI, and Standigm Expander/Insight for drug repurposing. The AI SaaS suite includes STELLA (MPO platform), SPICA (novelty assessment), QIP-ADMET (ADMET prediction), GT-AutoML (automated QSAR modeling), and ASK-LLM (knowledge graph-to-text generation). Standigm provides end-to-end solutions ranging from discovery to active material exploration, optimization, and derivation of preclinical candidate materials, reportedly reducing material optimization from 4.5 years to 1.5 years.

Differentiator

Problem solved

Functional benefit

Brands

• ASK™: AI-aided novel target identification platform for customized drug target discovery.
• ASK-LLM™
• BEST™
• SPICA™
• QIP-ADMET™
• STELLA™
• GT-AutoML™
• Standigm GPT

Products and services

• Standigm ASK AI-aided drug target identification platform providing comprehensive database integration from literature and public databases, customizable machine learning approaches for novel target insights, and an interactive user interface for target-disease relationship analysis. Built on Standigm BioMap knowledge graph with 30K targets, 10K phenotypes, 5K drugs, 4.3M relations, 36 databases, and 97K publications.
• Standigm BEST Comprehensive compound design platform comprising multiple drug design AI modules including ChemMap (deep learned chemical space), GPN (Graph Point Network for 2D/3D structural information), Monet (moiety-based molecular networks for derivative enumeration), NoSH (novel scaffold hopping), and IDEA-STAR (virtual screening combining multi-pose docking and active learning). Addresses all scenarios from hit identification to lead optimization.
• STELLA Innovative MPO (Multi-Parameter Optimization) platform for hit-to-lead optimization, powered by genetic algorithms and advanced AI. Accelerates drug candidate creation and refinement from concept to market-ready molecular design with multi-objective optimization capabilities. Sold as cloud-based AI SaaS.
• SPICA AI-based patentability prediction model that swiftly computes novelty prospects for new molecular structures born from AI synthesis. Delivers rapid, precise novelty evaluations ensuring a clear path toward patent protection. Sold as cloud-based AI SaaS.
• QIP-ADMET Quantum-Informed Pretrained ADMET prediction models trained on extensive datasets including experimental data, in silico quantum mechanical (QM) data, and molecular descriptors. Delivers swift and reliable predictions for Absorption, Distribution, Metabolism, Excretion, and Toxicity to propel candidates toward clinical success. Sold as cloud-based AI SaaS.
• GT-AutoML Automated QSAR modeling platform supporting both ligand-based and structure-based approaches. Automates labor-intensive steps such as ligand alignment and integrates multi-level molecular descriptors from state-of-the-art foundation models. Sold as cloud-based AI SaaS.
• ASK-LLM Retrieval Augmented Generation (RAG) system that transforms knowledge graphs into actionable text insights. Advanced hypothesis-generating assistant that guides researchers to faster, more reliable conclusions with contextually curated references and streamlined summaries. Sold as cloud-based AI SaaS.
• Standigm Magic Integration of Workflow AI from target identification to lead optimization, enabling end-to-end automated drug discovery workflows.
• Standigm Expander Drug repurposing platform for identifying novel indications for existing compounds.
• Standigm Insight Enhanced drug repurposing platform for improved target-disease relationship analysis.

Quantifiable outcome

• Reduced material optimization timeline from industry average of 4.5 years to 1.5 years (67% reduction)
• +2 more outcomes

Named customers10 records

Segments2 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

Yes

API docs

API detail

Core technology

AI maturity

App detail

AI capability10 records

Feature12 records

Partnerships

13 partnerships are on record, tiered flagship, key and standard.

• SK chemicalsflagshipStrategic or Co-development PartnerMajor pharmaceutical partnership with SK chemicals for automated workflow AI technology collaboration. SK chemicals uses Standigm's AI to continuously develop optimal drug candidates in shorter periods and lower cost than traditional methodologies. Both companies report remarkable research results from the collaboration.
• Hanmi PharmaceuticalflagshipStrategic or Co-development PartnerStrategic partnership with Hanmi Pharmaceutical, one of Korea's largest pharmaceutical companies, for AI-driven drug discovery collaboration.
• HK inno.NkeyStrategic or Co-development PartnerPartnership with HK inno.N for AI-powered drug discovery services and collaborative research.
• Samjin Pharmaceuticals Co., Ltd.keyStrategic or Co-development PartnerCollaboration with Samjin Pharmaceuticals using Standigm's AI technology to produce drug candidates with drug-patentability by maintaining physicochemical properties and modifying structures.
• SK Inc. C&CkeyStrategic or Co-development PartnerPartnership with SK Inc. C&C as a leading digital transformation company to establish an ecosystem for new AI drug discovery platforms in the global pharmaceutical & bio market.
• Milner Therapeutics InstitutekeyStrategic or Co-development PartnerPartnership with Milner Therapeutics Institute at University of Cambridge for global research collaboration in AI-driven drug discovery.
• Ewha Womans UniversitykeyStrategic or Co-development PartnerAcademic partnership with Ewha Womans University for customized target discovery research using Standigm's AI technology to extract important information from vast databases while integrating specific research context and private data.
• Institut Pasteur KoreakeyStrategic or Co-development PartnerResearch collaboration with Institut Pasteur Korea for discovering active anti-tubercular compounds using Standigm's AI approach based on previous HTS assay results with Mycobacterium tuberculosis.
• Ajou University HospitalkeyStrategic or Co-development PartnerPartnership with Ajou University Hospital using Standigm Insight platform for rational drug repurposing, successfully finding existing drugs showing efficacy for intractable diseases without laborious high-throughput phenotypic screening.
• Korea Institute of Science and Technology (KIST)keyStrategic or Co-development PartnerResearch partnership with KIST for collaborative AI-driven drug discovery projects.
• LigaChem Biosciences, Inc. (LCB)standardStrategic or Co-development PartnerListed partnership with LigaChem Biosciences for potential collaborative research in drug discovery.
• Curome BiosciencesstandardStrategic or Co-development PartnerListed partnership with Curome Biosciences for potential collaborative research.
• Cure Mito FoundationstandardStrategic or Co-development PartnerPartnership with Cure Mito Foundation for research in mitochondrial diseases.

Scale indicators6 records

Recent moves7 records

Expansion highlights6 records

Direct peers

• Insilico Medicine: Insilico Medicine is a leading AI-driven drug discovery company with end-to-end target identification, generative chemistry, and clinical-stage pipeline (e.g., INS018_055 in IPF). Directly comparable to Standigm's AI drug discovery platform across target ID, hit-to-lead, and proprietary pipeline, though larger and more advanced.
• Recursion Pharmaceuticals: Recursion combines high-throughput biology with AI/ML for drug discovery across multiple therapeutic areas. Operates a platform-plus-pipeline model similar to Standigm, with partnerships (Roche, Genentech, Bayer) and proprietary pipeline programs.
• Schrödinger, Inc. Schrödinger provides computational chemistry/A SaaS platform (LiveDesign) used by major pharma, alongside an internal pipeline. Closely comparable to Standigm in delivering physics-based and AI drug discovery software plus proprietary programs.
• Atomwise: Atomwise applies AI (AtomNet) to small-molecule hit discovery with pharma partnerships. Comparable to Standigm in target identification and compound design, with similar commercial model of pharma collaborations plus proprietary programs.
• Exscientia: Exscientia is an AI-driven precision medicine company with end-to-end discovery capabilities and pharma partnerships (e.g., Bristol Myers Squibb). Directly comparable AI drug discovery peer with both platform and pipeline assets.
• XtalPi: XtalPi combines AI, quantum physics, and robotics for small-molecule drug discovery with global pharma partnerships. Comparable AI+CRO model to Standigm, with larger scale and broader wet-lab integration.
• BenevolentAI: BenevolentAI uses knowledge graphs and AI for drug discovery with programs in neurodegeneration and rare diseases. Comparable to Standigm's knowledge-graph-based target ID approach, with similar AI-platform-plus-pipeline structure.

Emerging players

• Iambic Therapeutics: Iambic develops AI-driven small-molecule discovery platforms (including NeuralPLexer for protein-ligand structure prediction). Overlaps with Standigm's generative chemistry and structure-based design capabilities as an emerging AI-native competitor.

Broad incumbents

• Google DeepMind (Isomorphic Labs): Isomorphic Labs (Alphabet/DeepMind) builds on AlphaFold to commercialize AI drug discovery with major pharma partnerships (Eli Lilly, Novartis). A well-capitalized broad incumbent that could outcompete smaller AI platforms like Standigm on scale, data, and brand.
• NVIDIA (BioNeMo / Clara): NVIDIA provides BioNeMo and Clara platforms for AI-driven drug discovery and life sciences. As an infrastructure incumbent, it competes indirectly with Standigm by enabling pharma to build internal AI capabilities rather than buying from vendors like Standigm.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks5 records

Key highlights7 records

Customer concentration

• YouTubeyoutube.com/@standigm4563
• LinkedInlinkedin.com/company/13185046
• Facebookfacebook.com/standigm

Revenue estimate

Valuation estimate

Number of profiles

Profiles7 records

Funding overview

Funding rounds8 records

Investors15 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Standigm